Novo will drop its U.S. list price for its Fiasp by 75% and for Tresiba by 72%, the Danish company said in a release. The new ...

Novo Nordisk said it will cut the list prices in the U.S. of two of its insulin drugs, Tresiba (insulin degludec) and Fiasp ...

Findings from CONFIRM - a large real-world evidence study - compared the effectiveness of Tresiba injections versus insulin glargine U300, marketed as Toujeo and sold by Sanofi. The study included ...

Danish drug maker Novo Nordisk said on Thursday it will reduce the U.S. list prices of two insulin products by more than 70% ...